Automera, a new biotechnology company based in Singapore, has secured $16 million in Series A funding co-led by Accelerator Life Science Partners (ALSP) and ClavystBio.

Automera said in a statement on Wednesday that the funding also saw participation from Singapore-based global investor EDBI, Xora Innovation, and other undisclosed investors.

Joining the Board of Directors are Loong Wang, from Automera, Dr. Alice Chen and Thong Q. Le, from ALSP, and Dr. Wen Qi Ho, from ClavystBio.

“Automera was founded on the premise that improving health outcomes for people with serious diseases requires new technologies that make it easier, faster, and less expensive to develop safe and effective medicines,” said Loong Wang, Co-Founder of Automera.

He believes that the firm’s autophagy-targeting chimera small molecules (AUTAC) platform is one such technology, with broad potential across multiple disease indications that are difficult to treat with current therapeutic approaches.

“We greatly value the business and financial support that ALSP provides and are proud that leading healthcare investors are participating in Automera’s Series A financing,

“With these resources, Automera is well positioned to deploy our AUTAC platform toward the development of potentially transformative therapies,” he added.

Automera is a new biotechnology company that focuses on the development of AUTACs.

The company was established by co-founders Associate Professor Michael Lazarou, Loong Wang, and Taiyang Zhang at Talo Labs Pte Ltd.

Automera’s AUTAC platform is a next-generation approach to realizing the potential of targeted protein degradation (TPD) as a therapeutic modality.

TPD, an emerging field of novel therapeutics, catalyzes the degradation of disease-related proteins while retaining the benefits of small molecules.

Automera’s AUTAC platform is designed to generate novel therapies that degrade not only disease-related proteins but also protein aggregates, organelles, and pathogens.

Automera opined that AUTACs have the potential to provide a more flexible approach to protein degradation than existing approaches such as proteolysis-targeting chimeras (PROTACs) to trigger protein degradation.

“ALSP has long been interested in helping to drive biopharma innovation emerging in Singapore,” said Alice Chen, Executive Vice President at ALSP and Automera board member.

As the firm’s first investment in Singapore, she said Automera exemplifies the innovative scientific and translational research ongoing in the region.

“We plan to leverage ALSP’s unique company-building capabilities in Singapore, and we look forward to working with the broader Singapore community to enhance the platform technologies and early-stage therapeutic programs that Automera will develop,

“We are honored to co-lead Automera’s Series A financing with our partners at ClavystBio and are excited about expanding Automera’s operations in the months ahead,” she added.

ALSP is an early-stage life science accelerator and investment firm that creates and builds next-generation biotechnology companies centered on innovative science.

The firm catalyzes the development and commercialization of breakthrough biotechnology innovations by providing a holistic toolkit and leveraging its network and entrepreneurial expertise to accelerate the establishment and operation of early-stage biotechnology companies.

ALSP’s portfolio companies are backed by renowned life science investors and are comprised of industry-leading, transformative companies, including KayoThera, Inc., Lodo Therapeutics (acquired by Zymergen, now Ginkgo BioWorks), Petra Pharma (acquired by a global pharmaceutical company), Proniras Corporation, and Rodeo Therapeutics (acquired by Amgen Inc.).

It is noted that Automera has assembled a distinguished scientific advisory group that includes Associate Professor Michael Lazarou, Automera’s Scientific Co-Founder at the Walter and Eliza Hall Institute of Medical Research (WEHI) and the Monash Biomedicine Discovery Institute, Dr. Nicholas Ktistakis from Babraham Institute, Dr. Gene Yeo from the University of California San Diego (UCSD) and Dr. Kendall Mohler from ALSP.

Augmented with quantum chemistry and artificial intelligence (AI) enabled drug discovery tools, Automera opined that AUTACs have the broad potential to rapidly generate novel therapeutic leads for a range of diseases.

Automera will also initially focus its product development efforts to treat cancer.

“ClavystBio is excited to be building new ventures in Singapore through partnerships with young entrepreneurs like Loong Wang and his team at Automera, and smart capital investors like ALSP,” said Wen Qi Ho, Therapeutics Lead at ClavystBio.

“Our mission is to accelerate the commercialization of breakthrough innovations like the AUTAC platform for health impact, and we welcome Automera and ALSP to Singapore’s growing life sciences translational community,” she said.

ClavystBio was conceived and launched by Singaporean state-owned fund Temasek to be a venture builder, trusted partner, and keystone to catalyze global health solutions from Singapore.

Since its inception in 2022, ClavystBio has committed over $220 million to biotech, diagnostics, and digital health companies, as well as early-stage venture capital funds.

The firm’s mission is to accelerate the commercialization of life science breakthroughs into health impact.

It invests and partners with innovators, entrepreneurs, and founders to launch and grow global companies in Singapore.

Johnson & Johnson Innovation partners Singapore Economic Development Board to transform Singapore’s life science innovation ecosystem